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Background: Increasing evidence indicates that the TGFβ/Smad signaling pathway plays a prominent role in tumor
initiation, progression, and metastasis. Therefore, we investigate the expression of p-Smad2 in surgical resection
specimens from non-small cell lung cancer, and evaluate the prognostic significance of p-Smad2 expression in
stromal fibroblasts and cancer cells for patients with clinical stage I to IIIA non-small cell lung cancer.
Methods: The immunohistochemical expression of p-Smad2 was evaluated in 78 formalin-fixed paraffin-embedded
surgical resection specimens from clinical stage I to IIIA non-small cell lung cancer. Correlations between p-Smad2
expression and clinicopathologic characteristics were determined by Chi-square test. The prognostic significance of
p-Smad2 expression in stromal fibroblasts and cancer cells with regard to overall survival was determined by
Kaplan-Meier.
Results: There were 38.5% (30/78) and 92.3% (72/78) patients with high p-Smad2 expression in stromal fibroblasts
and cancer cells, respectively. There was a positive correlation between the p-Smad2 expression level in stromal
fibroblasts and the p-Smad2 expression level in cancer cells (χ2 = 4.176, P =0.045). No significant correlation of
p-Smad2 expression in stromal fibroblasts or cancer cells with any of clinicopathologic characteristics was found.
The 3-year overall survival rates with low and high p-Smad2 expression in stromal fibroblasts were 53.7% and
37.7%, respectively (χ2 = 3.86, P = 0.049). No significant association was found between low and high p-Smad2
expression in cancer cells with respect to overall survival, respectively (χ2 = 0.34, P =0.562).
Conclusions: The results suggested that high p-Smad2 expression in stromal fibroblasts predicted poor survival in
patients with clinical stage I to IIIA non-small cell lung cancer.
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Non-small cell lung cancer (NSCLC) accounts for 80%
of all lung cancers and is the most common cause of
cancer-related death worldwide [1,2]. In spite of recent
advances in surgical techniques, chemotherapy, radio-
therapy and many kinds of new strategies of treatment,
long-term survival is achieved in only 5 to 10% of
NSCLC patients [3]. The molecular mechanisms in-
volved in lung carcinogenesis are associated with dysreg-
ulation of many signaling pathways. Among these,* Correspondence: luxueguan@163.com
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unless otherwise stated.transforming growth factor-β (TGF-β) signaling plays an
important role in development and progression of lung
cancer [4-6]. TGF-β displays a dual role in cancer devel-
opment. In early tumorigenesis, it functions as a tumor
suppressor, whereas in later stages of tumor progression,
it acts as a tumor promoter [7]. TGF-β is synthesized as
a latent, extracellular matrix (ECM)-bound molecule,
which is activated via proteolytic and nonproteolytic
pathways. Activated TGF-β binds to TGF-β type-II
receptor (TβRII), which subsequently recruits and
transphosphorylates the type ITGF-β receptor activin
receptor-like kinase (ALK)-5. Subsequently, intracellular
signaling is mediated by the family of Smad proteinstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Squamous carcinoma 41 (52.6)
Adenocarcinoma 29 (37.2)
Adenosquamous carcinoma 3 (3.8)









Treatment modality - Curative resection
Yes 78 (100.0)
No 0 (0)
Treatment modality - Adjuvant chemotherapy
Yes 64 (82.1)
No 14 (17.9)
Treatment modality - Postoperative radiotherapy
Yes 17 (21.8)
No 61 (78.2)
*According to Union for International Cancer Control/American Joint
Committee on Cancer (6th edition) stage system.
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activated Smad2 and Smad3 form heteromeric complexes
with the common mediator Smad4 and then translocate
to the nucleus where they act as ligand-induced tran-
scription regulators of target genes [8,9].
In recent years, increasing evidence indicates that the
progression of tumors toward a malignant phenotype
does not only depend on the cell-autonomous properties
of cancer cells themselves but is also deeply influenced
by tumor stroma [10]. The activated stromal fibroblasts,
termed cancer-associated fibroblasts (CAFs), play a
prominent role in tumor initiation, progression, and me-
tastasis [11,12]. TGF-β is implicated in the activation of
tumor stromal fibroblasts, leading to the generation of
CAFs and to promoting tumor stromal formation
through the TGFβ/Smad signaling pathway [13-15].
Several previous studies have demonstrated that
Smad2 expression level in cancer cells appeared to be
correlated with tumor development and prognosis in pa-
tients with gastric carcinoma, glioma, breast cancer,
colorectal cancer, and esophageal squamous cell carcin-
oma [16,17]. However, not much is known regarding the
prognostic value of Smad2 expression in lung cancer
cells. In addition, there is especially a lack of evidence
about the prognostic significance of Smad2 expression
in stromal fibroblasts of lung cancer. In the present
study, therefore, we investigated the p-Smad2 expression
in surgical resection specimens from NSCLC to evaluate
the prognostic significance of p-Smad2 expression in
stromal fibroblasts and cancer cells for patients with
clinical stage I to IIIA NSCLC.
Methods
Patients and surgical resection specimen selection
The paraffin-embedded postoperative tumor specimens
were obtained from the tissue bank in the Department
of Pathology, the Second Affiliated Hospital of Soochow
University, between January of 2009 and June of 2011.
We retrospectively recruited 78 tumor specimens from
patients with clinical stage I to IIIA NSCLC. The ethics
committee of the Second Affiliated Hospital of Soochow
University approved the current project, and waived the
need for written informed consent.
The main characteristics of the 78 patients with clin-
ical stage I to IIIA NSCLC were summarized in Table 1.
Ages of the patients in this study range from 41 to
81 years (median, 63 years). According to the AJCC/
UICC (6th edition), there were 20 patients with stage І,
9 patients with stage II, and 49 patients with stage IIIA.
All patients underwent curative resection. Systemic adju-
vant treatment was administered to 64 patients. The
chemotherapeutic regimen used was a cisplatin-based
doublet. Seventeen patients received thoracic postopera-
tive radiotherapy.Immunohistochemistry
Serial slides, each 3-um thick, were cut from paraffin-
embedded tissue. One slide was stained with hematoxylin
and eosin (HE). Immunohistochemical staining was per-
formed on another slide, using the two-step procedure.
The anti-human p-Smad2 rabbit polyclonal antibody
(Ser465/467) (Chemicon, Billerica, MA, USA; diluted 1:
500) was used. After de-paraffinization and hydration,
the slides were subjected to antigen retrieval by pressure-
cooking for 30 minutes. Endogenous peroxidase activity
was neutralized using peroxide block placement on the
slides for 15 minutes at room temperature. The slides
were then incubated with anti-p-Smad2 antibody for
40 minutes at 4°C. This was followed by incubation with
peroxidase-conjugated polymer (ChemMate EnVision/
HRP; Gene Tech, Shanghai, China) for 30 minutes
at room temperature. The chromogen reaction was
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Shanghai, China) tetrahydrochloride for 10 minutes.
Finally, hematoxylin was used as a light nuclear counter-
stain. The negative control used was an IgG2b isotype
antibody (Dako), ensuring the same concentration of
immunoglobins as for anti-p-Smad2.
Assessment of p-Smad2 expression
All slides were evaluated independently by two experi-
enced pathologists (Li F and Zhang Y). Ten high-power
fields were selected randomly for each slide. The expres-
sion levels of each marker in cancer cells and stromal fi-
broblasts were independently evaluated. The percentage
of positive-staining cells were graded on a scale of 0to 3,
with less than 5% positive-staining cells as grade 0, 5 to
25% as grade 1, 26 to 50% as grade 2, and more than
50% as grade 3. The intensity of staining was also graded
on a scale of 0 to 2, with negative to weak intensity as
grade 0, weak to moderate intensity as grade 1, and
moderate to strong intensity as grade 2. After that, the
percentage score was multiplied by the intensity score. A
final score between 0 and 2 was defined as low expres-
sion, and a score higher than 2 was defined as high
expression.
Statistical analysis
The association between p-Smad2 expression in cancer
cells or stromal fibroblasts and clincopathologic charac-
teristics was examined with a Chi-square test. Overall
survival (OS) rates were performed by the Kaplan-Meier
method and log-rank test. Overall survival duration wasFigure 1 Expression of p-Smad2 in stromal fibroblasts and in cancer
(NSCLC) (magnification × 200).defined from the day of surgery to the day of death or
last follow-up. For all tests, a two-sided P <0.05 was con-
sidered significant.
Results
Expression of p-Smad2 in stromal fibroblasts and cancer
cells
The expression of p-Smad2 was confined to the nucleus.
The expression level of p-Smad2 in stromal fibroblasts
ranged from 12.5% to 85.8%, and its expression level in
cancer cells ranged from 19.3% to 94.2%. There were
38.5% (30/78) and 92.3% (72/78) patients with high p-
Smad2 expression in stromal fibroblasts and cancer cells,
respectively (Figure 1). The analysis revealed that there
was a positive correlation between the p-Smad2 expres-
sion level in stromal fibroblasts and the p-Smad2 expres-
sion level in cancer cells (χ2 = 4.176, P = 0.045). With
regard to age, gender, clinical stage, pathologic type and
differentiation, there was no significant correlation of p-
Smad2 expression in stromal fibroblasts or cancer cells
with any of clinicopathologic characteristics (Table 2).
Prognosis analysis
The median duration of follow-up for these patients was
26 months (range, 1 to 55 months). The Kaplan-Meier
plots showed that the 3-year OS rate of all patients was
47.6%. The 3-year OS rates with clinical stage I + II and
IIIA were 68.0% and 32.8%, respectively (χ2 = 6.27, P =
0.012; Figure 2a). The 3-year OS rates with low and high
p-Smad2 expression in stromal fibroblasts were 53.7%
and 37.7%, respectively (χ2 = 3.86, P = 0.049; Figure 2b).cells by immunohistochemistry in non-small cell lung cancer
Table 2 Association between p-Smad2 expression in cancer cells or stromal fibroblasts and clinicopathologic
characteristics
p-Smad2 expression in cancer cells p-Smad2 expression in stromal fibroblasts
Variables Number of patients Low (%) High (%) P Low (%) High (%) P
Gender
Male 55 5 (9.1) 50 (90.9) 0.473 32 (58.2) 23 (41.8) 0.346
Female 23 1 (4.3) 22 (95.7) 16 (69.6) 7 (30.4)
Age (years)
≤63 41 2 (4.9) 39 (95.1) 0.326 23 (56.1) 18 (43.9) 0.298
>63 37 4 (10.8) 33 (89.2) 25 (67.6) 12 (32.4)
Pathologic type
Squamous carcinoma 41 2 (4.9) 39 (95.1) 0.560 24 (58.5) 17 (41.5) 0.605
Adenocarcinoma 29 3 (10.3) 26 (89.7) 20 (69.0) 9 (31.0)
Adenosquamous carcinoma 3 0 (0) 3 (100.0) 2 (66.7) 1 (33.3)
Large cell carcinoma 5 1 (20.0) 4 (80.0) 2 (40.0) 3 (60.0)
Pathologic differentiation
High 5 0 (0) 5 (100.0) 0.562 4 (80.0) 1 (20.0) 0.679
Median 50 5 (10.0) 45 (90.0) 30 (60.0) 20 (40.0)
Low 23 1 (4.3) 22 (95.7) 14 (60.9) 9 (39.1)
Clinical Stage*
I + II 29 4 (13.8) 25 (86.2) 0.120 20 (69.0) 9 (31.0) 0.300
IIIA 49 2 (4.1) 47 (95.9) 28 (57.1) 21(42.9)
*According to Union for International Cancer Control/American Joint Committee on Cancer (6th edition) stage system.
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low and high p-Smad2 expression in cancer cells with
respect to OS, respectively (χ2 = 0.34, P = 0.562).
Discussion
Because p-Smad2 is a primary step and intracellular sig-
naling effector for the mediation of intracellular signal-
ing of TGFβ [18], we focused our study on p-Smad2
expression on NSCLC. The present study demonstrated
that p-Smad2 expression was confined to the nucleus,
and its expression level in cancer cells was high in 72
(92.3%) of 78 NSCLC. However, Shinto et al. [16] found
that the high expression level of p-Smad2 in cancer cells
was existed in 63 (47%) of 135 gastric carcinomas. de
Kruijf et al. [10] found that 129 (26.9%) of 505 breast
cancers had high nuclear expression of p-Smad2 in can-
cer cells. These results suggest that the expression level
of p-Smad2 in cancer cells is associated with tumor type.
Recently, a few studies have demonstrated that Smad2
expression level in cancer cells is correlated with tumor
development and prognosis. Previous studies on eso-
phageal squamous cell carcinoma, breast cancer and
colorectal cancer demonstrated that loss of Smad2 ex-
pression was correlated with tumor development and
poor prognosis [19-21]. Conversely, Shinto et al. [16]
found that the prognosis for p-Smad2-high patients with
advanced stage gastric carcinoma was significantlypoorer than that of p-Smad2-low patients. de Kruijf
et al. [10] found that high expression of p-Smad2 was
substantially associated with a worse prognosis in breast
cancer. Similarly, the positive p-Smad2 expression was
reported to be correlated with tumor proliferation and
poor prognosis in a study of 52 patients with glioma
[22]. At the same time, some studies demonstrated that
p-Smad2 expression level was not related to the progno-
sis in patients with renal clear cell carcinoma and colo-
rectal cancer [23,24]. In the present study, we also found
that the expression level of p-Smad2 in cancer cells was
not associated with any of clinicopathologic characteris-
tics and 3-year overall survival in patients with clinical
stage I to IIIA NSCLC. These studies suggest that the re-
sults are inconsistent, even completely opposite in the
same tumor type, and the further study is needed.
In recent years, increasing evidence indicates that
activating TGFβ/Smad signaling pathway promotes the
generation of CAFs and tumor stromal formation, and
plays prominent roles in tumor initiation, progression,
and metastasis [11-15]. So we further investigated p-
Smad2 expression in stromal fibroblasts and its prognos-
tic significance in NSCLC. The results found that 38.5%
(30/78) patients with NSCLC had high p-Smad2 ex-
pression in stromal fibroblasts. Hawinkels et al. [9]
found that 89% and 42% of 88 patients with colorectal
cancer were observed with nuclear p-Smad2 expression
Figure 2 Kaplan-Meier curves for patients with clinical stage I to IIIA non-small cell lung cancer (NSCLC). a. different clinical stage groups;
b. different p-Smad2 expression groups.
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we also found that there was a positive correlation be-
tween the p-Smad2 expression level in stromal fibro-
blasts and the p-Smad2 expression level in cancer cells
(P = 0.045). The high p-Smad2 expression in stromal
fibroblast was associated with a trend for poor overall
survival in patients with clinical stage I to IIIA NSCLC.
As we all know, this is the first report that focuses on
prognostic significance of p-Smad2 expression in stromal
fibroblasts.Conclusions
In conclusion, the results suggest that high p-Smad2 ex-
pression in stromal fibroblasts predicted poor survival in
patients with clinical stage I to IIIA NSCLC. However,
this study is limited by the relatively small number of
patients, and more and larger studies are required.
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